New York Times(NYT)

Search documents
Nongshim Shin Ramyun Light Ups New York Times Square with 'KPop Demon Hunters'
Prnewswire· 2025-10-20 12:30
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Nongshim carried out a global campaign at New York Times Square to celebrate the launch of Shin Ramyun in collaboration with Netflix's hit animated film 'KPop Demon Hunters'. As known for "The Crossroads of the World" and attracting over 450,000 visitors daily, Times Square served as the stage for global consumers to directly taste and enjoy the Shin Ramyun brand through a variety of interactive activities that seamlessly connected both online and offline experiences. ...
The Capital Link Issues Independent Analysis on LuxUrban Hotels' New York Sales-Tax Compliance
Globenewswire· 2025-10-16 21:17
Core Insights - The Capital Link published an independent analysis titled "They Got It Wrong," examining LuxUrban Hotels Inc.'s compliance with New York State and City sales and occupancy tax requirements from 2020 to 2025 [1][4] Compliance Findings - The analysis concludes that LuxUrban's tax position aligns with New York state and city laws, indicating compliance with applicable tax regulations [2] - A significant portion of taxable transactions was processed through third-party online travel agencies (OTAs), which are responsible for collecting and remitting sales and occupancy taxes under New York law [2] Implications and Clarifications - The report aims to clarify claims of significant unpaid taxes, suggesting that public narratives may have exaggerated potential liabilities [3] - It emphasizes the importance of careful interpretation of tax filings and enforcement actions in the hospitality sector, which has broader implications for tax reporting and investor information [3]
The ‘New York Times' and others announce they are not signing the Pentagon's new press rules
Fastcompany· 2025-10-14 18:31
News organizations including The New York Times, The Associated Press and the conservative Newsmax television network said Monday they will not sign a Defense Department document about its new press r... ...
OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting
Newsfile· 2025-10-09 11:40
Core Insights - OS Therapies received a positive regulatory update from the European Medicines Agency (EMA) following a meeting with the Dutch Medicines Evaluation Board (MEB) on October 6, 2025, regarding its OST-HER2 Phase 2b clinical trial for osteosarcoma [2][3] Regulatory Developments - The meeting aligned on key areas such as safety, non-clinical data, and chemistry, manufacturing, and controls (CMC) data, supporting the ongoing clinical trial [3][8] - The overall survival results from the trial, showing statistically significant final two-year data, may serve as a primary endpoint for conditional marketing authorization (CMA) [3][8] - A formal EMA Scientific Advice is anticipated in December 2025, establishing a potential pathway for a confirmatory randomized clinical development program [4][10] Clinical Trial Insights - The safety profile from the Fully Resected Osteosarcoma clinical study was confirmed as positive, with data from over 500 patients treated across four other therapeutic indications potentially supporting a CMA [8] - The rapporteur indicated that overall survival (OS) could provide a stronger measure of clinical benefit compared to 12-month Event-Free Survival (EFS) [8] - Efficacy data from other settings, such as recurrent, unresectable pulmonary metastatic osteosarcoma, could be incorporated into a post-market confirmatory clinical development program [8] Market Access and Future Plans - OS Therapies has commenced the Marketing Authorisation Application (MAA) submissions process with the UK MHRA, which has granted an expedited Market Access Scientific Advice Meeting [6] - The company plans to pursue a conditional marketing authorization while advancing a global randomized clinical study to evaluate OST-HER2 in various osteosarcoma clinical settings [10] - OST-HER2 has received multiple designations from the U.S. FDA and EMA, including Rare Pediatric Disease Designation and Fast-Track status [11]
OS Therapies to Participate in Fall 2025 Conferences and Events
Newsfile· 2025-10-07 15:50
Core Insights - OS Therapies is actively participating in multiple conferences and events in October 2025, showcasing its commitment to advancing cancer treatment and engaging with industry stakeholders [1][2][3][4][5]. Company Overview - OS Therapies Inc. is a clinical-stage biotechnology company focused on developing treatments for Osteosarcoma and other solid tumors, with its lead asset being OST-HER2, an immunotherapy targeting the HER2 protein [5][6]. - OST-HER2 has received several designations from the U.S. FDA, including Rare Pediatric Disease Designation, Fast-Track, and Orphan Drug designations, indicating its potential significance in treating rare diseases [5]. - The company reported positive results from its Phase 2b clinical trial of OST-HER2, demonstrating statistically significant benefits in the 12-month event-free survival primary endpoint for patients with recurrent, fully resected, lung metastatic osteosarcoma [5]. Upcoming Events - OS Therapies will participate in the Cell and Gene Meeting on the Mesa from October 6-8, 2025, in Phoenix, AZ, focusing on partnering and one-on-one meetings [2]. - The company will also attend the Roth Annual Healthcare Opportunities Conference on October 9, 2025, in New York City, where it will engage in meetings with potential investors [2]. - A workshop on advancing osteosarcoma drug development will take place on October 10, 2025, in Washington, DC, where OS Therapies management will be available for discussions [2]. - The BIOFuture 2025 event is scheduled for October 13-15, 2025, in New York City, featuring a spotlight panel and one-on-one meetings [3]. - The company will be present at the 52nd Daytime Emmy Awards on October 17, 2025, where its documentary "Shelter Me: Cancer Pioneers" has received two nominations [3]. - The Maxim Growth Summit will occur on October 22, 2025, in New York City, where corporate presentations and meetings will be held [4]. - OS Therapies will also participate in BIO - Europe from November 3-5, 2025, in Vienna, Austria, focusing on partnering and meetings [5]. Product Development - OST-HER2 has shown preclinical efficacy in various models of breast cancer and has been conditionally approved by the U.S. Department of Agriculture for treating canines with osteosarcoma [5]. - The company is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary technology for enhanced drug delivery [6].
Bari Weiss's Journey From a New York Times Resignation to a Top TV News Gig
WSJ· 2025-10-06 16:00
Core Insights - The former opinion editor and co-founder of the Free Press has been appointed as the editor in chief of CBS News [1] Company Overview - The new editor in chief brings a background in opinion journalism and media innovation to CBS News [1]
New York Times: Impressive Sub Growth, Questionable Valuation
Seeking Alpha· 2025-10-01 18:40
Group 1 - The Trump administration is characterized as highly active, generating significant news coverage [1] - Gary Alexander has extensive experience in technology companies and startups, contributing to industry insights [1] - His articles are featured on platforms like Seeking Alpha and popular trading apps such as Robinhood [1]
New York Times Bestselling Author of If You Give a Mouse a Cookie Publishes Corgi Picture Book with Michael Sampson Books
Businesswire· 2025-09-27 13:00
Core Insights - Laura Numeroff, a New York Times bestselling author, has released a new picture book titled "Max and Mama," illustrated by Masha Sudovykh, which emphasizes the bond between mother and son [1][2] - The book features engaging illustrations of corgis and aims to promote early childhood literacy through playful writing and relatable daily activities [1][2] - "Max and Mama" encourages children to embrace challenges and celebrate family connections [1] Publishing Industry - Laura Numeroff is renowned for her series based on "If You Give a Mouse a Cookie," which has sold over 72 million copies and has been adapted into an animated TV series [2] - The success of Numeroff's previous works includes significant recognition, such as being featured by celebrities and First Ladies during notable events [2] - The new release is positioned as a heartwarming addition to children's literature, appealing to both young readers and their families [2][4] Market Position - Michael Sampson Books is the publisher of "Max and Mama," indicating a focus on children's literature and family-oriented themes [1][4] - The book is part of a broader trend in the publishing industry that emphasizes social and emotional learning through engaging storytelling [7] - The release aligns with current market interests in books that foster family bonds and support early literacy [1][2]
The New York Times Company Declares Regular Quarterly Dividend
Businesswire· 2025-09-26 21:19
Core Points - The New York Times Company's Board of Directors declared a regular quarterly dividend of $0.18 per share on Class A and Class B common stock [1] - The dividend is scheduled to be payable on October 23, 2025, to shareholders of record as of the close of business on October 8, 2025 [1] - The New York Times Company is recognized as a trusted source of quality, independent journalism, with a mission to seek the truth and help people understand the world [1] - The company has more than 11 million subscribers [1]
Better Stock to Buy: Newsmax vs. The New York Times
The Motley Fool· 2025-09-25 07:25
Core Viewpoint - The comparison between Newsmax and The New York Times highlights the contrasting business models and financial performances of two media companies, with The New York Times being the more favorable investment option due to its profitability and growth metrics [1][12]. Business Model: Newsmax vs. The New York Times - Newsmax is a diversified media company with over 40 million viewers, primarily known for its linear cable channel and various digital platforms [4][5]. - The company generates revenue from cable subscriptions, advertising, and additional businesses such as nutraceuticals and insurance products [6]. - The New York Times has successfully transitioned to a digital-first model, with most of its revenue coming from digital subscriptions and advertising, despite challenges in digital ad profitability [7][8]. Financials: Newsmax vs. The New York Times - In Q2, Newsmax reported revenue of $46.4 million, an 18.4% increase year-over-year, but incurred an adjusted EBITDA loss of $3.8 million [9]. - The New York Times achieved revenue of $685.9 million in Q2, a 9.7% increase, with total subscribers rising to 11.9 million and an adjusted operating profit margin near 20% [10]. Valuation: Newsmax vs. The New York Times - Newsmax has a market cap of $1.15 billion and is not profitable, with a price-to-sales ratio of 9 [11]. - The New York Times, with a market cap of $9.5 billion, is profitable, trading at a lower price-to-sales ratio of 3.6 and a price-to-earnings ratio of 30, along with a dividend yield of 1.2% [11].